As previously reported, Wells Fargo downgraded Nevro to Underweight from Equal Weight with a price target of $5.50, down from $13. The firm notes the company reported a Q2 miss and lowered its 2024 guidance on market softness and competitive headwinds. Nevro also initiated a strategic review. Wells believes the growth and profit outlook remains uncertain into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: